GlassScriptPhysician profile
Richmond E Roeske
NPI 1720009913
$20,820.56
in general payments reported to CMS, 2019-2025
29 companies · $3,633 in 2025
The $3,633 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,967 · 2020: $1,494 · 2021: $4,344 · 2022: $1,950 · 2023: $2,220 · 2024: $4,211 · 2025: $3,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,963 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $600 · Grant: $450 · Honoraria: $27.78 · Entertainment: $15.33 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,963.27 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $600.00 |
| Grant | $449.55 |
| Honoraria | $27.78 |
| Entertainment | $15.33 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $11,330.46 | 2019-2025 | Clareon, Argos, Lensx |
| Sight Sciences, INC. | $2,042.65 | 2019-2025 | Omni Surgical System, Tearcare System, Sion Surgical Instrument |
| Abbvie INC. | $1,429.04 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Biotissue Holdings INC. | $912.90 | 2019-2025 | |
| Glaukos Corporation | $708.26 | 2019-2025 | Photrexa, Travoprost Intraocular Implant - Idose, Istent Infinite |
| Johnson & Johnson Surgical Vision, INC. | $704.99 | 2019-2025 | Tecnis Simplicity, Baerveldt Glaucoma Implant (250), Amo Phaco Needle |
| Rxsight INC | $688.73 | 2021-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Bausch & Lomb Americas INC. | $608.21 | 2023-2025 | Envista Envy Iol, Ic-8 Apthera Iol, Stellaris |
| Amgen INC. | $506.68 | 2024-2025 | Tepezza |
| Ivantis, INC | $273.44 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $221.64 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $209.97 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $199.54 | 2020-2021 | |
| Beaver-Visitec International, INC. | $159.98 | 2019 | |
| Allergan, INC. | $145.38 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $124.26 | 2023 | |
| Oyster Point Pharma, INC. | $102.67 | 2022-2025 | Tyrvaya, Ryzumvi |
| Eyevance Pharmaceuticals LLC | $81.22 | 2020-2022 | |
| Kala Pharmaceuticals, INC. | $61.48 | 2019-2021 | |
| Ocular Therapeutix, INC. | $60.78 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $44.06 | 2019-2020 | |
| Horizon Therapeutics Plc | $42.03 | 2022-2023 | Tepezza |
| Dompe US, INC. | $30.90 | 2022 | |
| Optos, INC. | $30.13 | 2021-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Genentech USA, INC. | $23.53 | 2025 | Vabysmo |
| Sun Pharmaceutical Industries INC. | $22.30 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $19.48 | 2023 | Quatera 700 |
| Shire North American Group INC | $18.34 | 2019 | |
| Glaxosmithkline, LLC. | $17.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richmond Roeske listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.